AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage and high mortality rates.
Standard-of-care chemotherapy is directed at eliminating the plasma cells that produce abnormal proteins, but does not adequately address new and existing amyloid buildup in organs, which can lead to organ failure and even death. CAEL-101’s novel approach is specifically designed to bind to the misfolded proteins and promote resolution. Strong Phase 1a/1b data support the potential for CAEL-101 combined with chemotherapy to be a comprehensive therapeutic option for AL amyloidosis patients.
For additional information on AL amyloidosis research, treatment and support, please visit the following:
The Amyloidosis Foundation is dedicated to supporting patients and families while promoting research, education and awareness.
The Amyloidosis Research Consortium is accelerating the development of advanced diagnostic tools and effective treatments for systemic amyloidosis through collaboration and innovation.
Myeloma UK works to ensure patients receive access to the right treatment at the right time and offers a range of support and advice services to patients, their family and friends aimed at helping them to deal with a myeloma or AL amyloidosis diagnosis.
Amyloidosis Support Groups’ primary purpose is to start and facilitate support groups, dedicated to providing education and empowerment to patients and caregivers. We are currently in 29 cities throughout the USA.